Meet the speakers from 2022



Development of RNA therapeutics & vaccines

We're excited to announce the following speakers at RNA Leaders, with more to come.

 Marc Abrams Senior Vice President, Discovery Research, Dicerna Pharmaceuticals

Marc Abrams

Senior Vice President, Discovery Research,
Dicerna Pharmaceuticals
Shalini Andersson, Chief Scientist, New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

Shalini Andersson

Chief Scientist, New Therapeutic Modalities & Head of Oligonucleotide Discovery
AstraZeneca
Alexandra Bause, Co-Founder, Investment Director & Head of VentureLabs, Apollo Health Ventures

Alexandra Bause

Co-Founder, Investment Director & Head of VentureLabs
Apollo Health Ventures
Marcel Blommers, CSO, Saverna Therapeutics

Marcel Blommers

CSO
Saverna Therapeutics
Siham Ceballos, Founder and Managing Partner, Bioartemis

Siham Ceballos

Founder and Managing Partner
Bioartemis
Sudha Chivukula, Head of RNA Technology, Research & External Innovation, Sanofi Pasteur

Sudha Chivukula

Head of RNA Technology, Research & External Innovation
Sanofi Pasteur
Jason Coleman

Jason Coleman

Clinical Application Scientist Lead
Precision Nanosystems
Alexandre Di Paolo Business Development Senior Manager at Trilink Biotechnologies

Alexandre Di Paolo

Business Development Senior Manager
Trilink Biotechnologies
Denis Drygin, CSO, Regulus Therapeutics

Denis Drygin

CSO
Regulus Therapeutics
Yaniv Erlich, CEO, Eleven Therapeutics

Yaniv Erlich

CEO
Eleven Therapeutics
Douglas Fambrough, CEO, Dicerna Pharmaceuticals

Douglas Fambrough

CEO
Dicerna Pharmaceuticals
Malgorzata Gonciarz, Associate Vice President, Genetic Medicine, Eli Lilly

Malgorzata Gonciarz

Associate Vice President, Genetic Medicine
Eli Lilly
Tamar Grossmanm Global Head of RNA and Targeted Therapeutics, Janssen

Tamar Grossman

Global Head of RNA and Targeted Therapeutics
Janssen
Nagy Habib, Founder and Head of R&D, MiNA Therapeutics

Nagy Habib

Founder and Head of R&D
MiNA Therapeutics
Bill Haney, CEO & Chairman, Skyhawk Therapeutics

Bill Haney

CEO & Chairman
Skyhawk Therapeutics
Lorna Harries, Co-Founder and CSO, Senisca

Lorna Harries

Co-Founder and CSO
Senisca
Philipp Heller, Projektmanager Innovation, Evonik

Philipp Heller

Projektmanager Innovation
Evonik
Aimee Jackson, CSO, Atalanta Therapeutics

Aimee Jackson

CSO
Atalanta Therapeutics
Anastasiia Kamenska, Director, Corporate Strategy, Novartis

Anastasiia Kamenska

Director, Corporate Strategy
Novartis
Malin Lemurell, Executive Director and Head of Medicinal Chemistry Early CVRM, Biopharmaceuticals R&D, Astra Zeneca

Malin Lemurell

Executive Director and Head of Medicinal Chemistry Early CVRM
Biopharmaceuticals R&D, Astra Zeneca
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly

Tim Luker

Vice President, Venture Science, Corp BD
Eli Lilly
Prof. Helen McCarthy, CEO, pHion Therapeutics

Helen McCarthy

CEO
pHion Therapeutics
Kathleen McCarthy, Co-Founder & Chief Scientific Officer, Skyhawk Therapeutics

Kathleen McCarthy

Co-Founder & Chief Scientific Officer
Skyhawk Therapeutics
Angele Maki, SVP, Business Development, ReCode Therapeutics

Angele Maki

SVP & Head of Business Development
ReCode Therapeutics
Melissa Moore, CSO, Moderna

Melissa Moore

CSO
Moderna
Johannes Muehl Senior Vice President, Finance, Exopharm

Johannes Muhl

Senior Vice President
Finance, Exopharm
Huw Nash, COO and CBO, Stoke Therapeutics-1

Huw Nash

COO and CBO
Stoke Therapeutics
Darach Neeson, COO, pHion Therapeutics

Darach Neeson

COO
pHion Therapeutics
Samir Ounzain, CEO and Scientific Co-Founder, HAYA Therapeutics

Samir Ounzain

CEO and Scientific Co-Founder
HAYA Therapeutics
Lykke Pedersen, Head of RNA Therapeutics, Abzu

Lykke Pedersen

Head of RNA Therapeutics
Abzu
Sylke Poehling, Senior Vice President and Global Head, Therapeutic Modalities, Roche

Sylke Poehling

Senior Vice President and Global Head, Therapeutic Modalities
Roche
Martin Rabel Field Application Scientist, Precision Nanosystems

Martin Rabel

Field Application Scientist
Precision Nanosystems
Umberto Romeo, Head of R&D, Corden Pharma GmbH

Umberto Romeo

Head of R&D
Corden Pharma GmbH
Kai Rossen, Chief Scientific Officer, EUROAPI

Kai Rossen

Chief Scientific Officer
EUROAPI
Branden Ryu,CEO, Biorchestra

Branden Ryu

CEO
Biorchestra
Suzanne Saffie-Siebert CEO at SiSaf

Suzanne Saffie-Siebert

CEO
SiSaf
Bernard Sagaert COO and Senior VP of Manufacturing, eTheRNA Immunotherapies

Bernard Sagaert

COO and Senior VP of Manufacturing
eTheRNA Immunotherapies
Laura Sepp-Lorenzino, CSO, Intellia Therapeutics

Laura Sepp-Lorenzino

CSO
Intellia Therapeutics
David Slack, CEO, Cend Therapeutics

David Slack

CEO
Cend Therapeutics
Peter Smith, Co-Founder, President and CEO, Remix Therapeutics

Peter Smith

Co-Founder, President and CEO
Remix Therapeutics
Brad Sorenson, Founder and CEO, Providence

Brad Sorenson

Founder and CEO
Providence Therapeutics
Thorsten Stafforst, Interfaculty Institute of Biochemistry, Eberhard Karls Universität Tübingen-1

Thorsten Stafforst

Interfaculty Institute of Biochemistry
Eberhard Karls Universität Tübingen
Dietrich Stephan

Dietrich Stephan

Founder and CEO
Neubase Therapeutics
Katarina Stenklo, Commercial Activation and End to End Solutions Leader, Cytiva

Katarina Stenklo

Commercial Activation and End to End Solutions Leader
Cytiva
Howard Stern, CSO, Korro Bio

Howard Stern

CSO
Korro Bio
Scott Taylor, Associate Director, Alliance Management, Trilink BioTechnologies

Scott Taylor

Associate Director, Alliance Management
Trilink BioTechnologies
Hans-Peter Vornlocher Managing Director Research Axolabs

Hans-Peter Vornlocher

Managing Director Research
Axolabs
Nathaniel Wang, CEO, Replicate Bioscience

Nathaniel Wang

CEO
Replicate Bioscience
Marie Wikstrom Lindholm, SVP and Head of Molecular Design, Silence Therapeutics

Marie Wikstrom Lindholm

SVP and Head of Molecular Design
Silence Therapeutics
Dominik Witzigmann,CEO & Co-Founder NanoVation Therapeutics-1

Dominik Witzigmann

CEO & Co-Founder
NanoVation Therapeutics
Matthew Wood, Professor of Neuroscience and Deputy Head, Medical Sciences Division, University of Oxford

Matthew Wood

Professor of Neuroscience and Deputy Head, Medical Sciences Division
University of Oxford
Klaas Zuideveld CEO, Versameb

Klaas Zuideveld

CEO
Versameb

DOWNLOAD BROCHURE